AbstractObjective To explore the efficacy and prognostic factors of postoperative intensity-modulated radiotherapy (IMRT) with or without chemotherapy in rectal cancer. Methods A retrospective analysis was performed on the clinical data of 218 patients with rectal cancer, who underwent postoperative IMRT in our hospital from January 2009 to December 2013.The Kaplan-Meier method was used to calculate survival rate;the log-rank test was used for survival difference analysis and univariate prognostic analysis;the Cox regression model was used for multivariate prognostic analysis. Results The follow-up rate was 97.7%. The 1-and 3-year overall survival rates were 90.8% and 75.2%, respectively, the 1-and 3-year disease-free survival rates were 85.3% and 70.5%, respectively, and the 1-and 3-year locoregional recurrence-free survival rates were 96.7% and 88.1%, respectively. The incidence of grade 3-4 acute adverse reactions was 28.4%, mainly manifested as leukopenia (13.8%) and diarrhea (11.0%). Univariate prognostic analysis showed that preoperative carcinoembryonic antigen (CEA) and CA199 levels, maximum tumor diameter, tumor location, degree of differentiation, depth of tumor invasion, number of lymph node metastases, TNM stage, perineural invasion, surgical procedure, total mesorectal excision, preoperative bowel obstruction, and preoperative anemia were the predictors of survival (P=0.006, 0.000, 0.000, 0.017, 0.000, 0.016, 0.000, 0.011, 0.001, 0.006, 0.037 and 0.010). Multivariate prognostic analysis showed that preoperative CEA level, tumor location, TNM stage, preoperative bowel obstruction, and preoperative anemia were the predictors of survival (P=0.000, 0.000, 0.000, 0.001 and 0.001). Conclusions Postoperative IMRT with or without chemotherapy is an effective method for rectal cancer with mild adverse reactions and high compliance. Preoperative CEA level, tumor position, TNM stage, preoperative bowel obstruction, and preoperative anemia are independent prognostic factors for the overall survival.
Hu Jing,Guo Qi,Yang Yongqiang et al. Analysis of efficacy and prognostic factors of postoperative intensity-modulated radiotherapy with or without chemotherapy in rectal cancer[J]. Chinese Journal of Radiation Oncology, 2015, 24(6): 633-637.
Hu Jing,Guo Qi,Yang Yongqiang et al. Analysis of efficacy and prognostic factors of postoperative intensity-modulated radiotherapy with or without chemotherapy in rectal cancer[J]. Chinese Journal of Radiation Oncology, 2015, 24(6): 633-637.
[1] Siegel R,Naishadham D,Jemal A.Cancer statistics,2013[J].CA Cancer J Clin,2013,63(1):11-30.DOI:10.3322/caac.21166. [2] Sobin LH,Gospodarowicz MK,Wittekind C.International Union Against Cancer (UICC).TNM classification of malignant tumours[M].7th ed. Oxford:Wiley-Blackwell,2009:100-105. [3] 殷蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学[M].4版.北京:中国协和医科大学出版社,2008:855-881. [4] Mod H,Crane CH,Palmer MB,et al. Intensity modulated radiation therapy (IMRT):differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma[J/OL].Radiat Oncol,2011,6:63[2015-01-02].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121606/.DOI:10.1186/1748－717X-6-63. [5] 钱立庭,宋永文,刘新帆,等.Ⅱ和Ⅲ期直肠癌根治术后放射治疗的疗效观察[J].中华放射肿瘤学杂志,2003,12(2):101-105.DOI:10.3760/j.issn:1004-4221.2003.02.007. [6] 卢宁宁,金晶,李晔雄,等.Ⅱ期和Ⅲ期直肠癌根治术后卡培他滨同期放化疗疗效及失败原因分析[J].中华放射肿瘤学杂志,2011,20(6):497-501.DOI:10.3760/cma.j.issn.1004-4221.2011.06.015. [7] Arbea L,Ramos LI,Martínez-Monge R,et al. Intensity-modulated radiation therapy (IMRT) vs.3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC):dosimetric comparison and clinical implications[J/OL].Radiat Oncol,2010,5:17[2015-01-02].http://www.ro-journal.com/content/5/1/17.DOI:10.1186/1748－717X-5-17. [8] Li JL,Ji JF,Cai Y,et al. Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer:a phase Ⅱ trial[J].Radiother Oncol,2012,102(1):4-9.DOI:10.1016/j.radonc.2011.07.030. [9] Gunderson LL,Sargent DJ,Tepper JE,et al. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer:a pooled analysis[J].Int J Radiat Oncol Biol Phys,2002,54(2):386-396.DOI:10.1016/S0360-3016(02)02945-0. [10] Wibe A,Syse A,Andersen E,et al. Oncological outcomes after total mesorectal excision for cure for cancer of the lower rectum:anterior vs.abdominoperineal resection[J].Dis Colon Rectum,2004,47(1):48-58.DOI:10.1007/s10350-003-0012-y. [11] den Dulk M,Putter H,Collette L,et al. The abdominoperineal resection itself is associated with an adverse outcome:the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer[J].Eur J Cancer,2009,45(7):1175-1183.DOI:10.1016/j.ejca.2008.11.039. [12] Shibutani M,Maeda K,Naqahara H,et al. Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage Ⅱ colorectal cancer[J].Anticancer Res,2014,34(7):3753-3758. [13] Ratto C,Sofo L,Ippoliti M,et al. Prognostic factors in colorectal cancer. Literature review for clinical application[J].Dis Colon Rectum,1998,41(8):1033-1049.DOI:10.1007/BF02237397. [14] Qiu MZ,Yuan ZY,Luo HY,et al. Impact of pretreatment hematological profile on survival of colorectal cancer patients[J].Tumor Biol,2010,31(4):255-260.DOI:10.1007/s13277-010-0024-x. [15] Piso P,Dahlke MH,Mirena P,et al. Total mesorectal excision for middle and lower rectal cancer:a single institution experience with 337 consecutive patients[J].J Surg Oncol,2004,86(3):115-121. [16] Fujita S,Shimoda T,Yoshimura K,et al. Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection[J].J Surg Oncol,2003,84(3):127-131. [17] Endreseth BH,Romundstad P,Myrvold HE,et al. Rectal cancer in the young patient[J].Dis Colon Rectum,2006,49(7):993-1001.DOI:10.1007/s10350-006-0558-6.
2015, Vol. 24 
